Matthew VonEsch is the AVP of Xeno and Regenerative Medicine Operations at United Therapeutics. Beginning with Wyeth Biopharma, followed by Human Genome Sciences, MedImmune, United Therapeutics, and Exelead; he has held positions of increasing responsibility in drug product manufacturing, including aseptic vial filling, automated inspection, and labeling and packaging operations. He is a recognized leader in advanced aseptic technologies, he is the former Chair of the ISPE Sterile Products Processing COP Steering Committee and has served as an author and reviewer numerous baseline guidance documents. In 2018, Matthew re-joined United Therapeutics to focus on solid/whole organ manufacturing for direct human transplantation with the hopes of solving the shortage of organs for transplantation. Matthew holds a BS in Biochemistry from the Merrimack College.